Simulations Plus Inc

DiBella’s 10b5‑1 sale of 1,000 Simulations Plus shares shows no ownership shift but signals exec confidence, hinting at upcoming partnerships and AI‑driven drug‑simulation gains.

Insider buying at Simulations Plus (SPMI) shows growing confidence and could spark a bullish turn—discover what this means for its drug‑simulation tech and future earnings.

Insider buy of 1,776 shares by Evans Sharlene at zero cost shows confidence in Simulations Plus, a niche simulation software firm amid a volatile market and emerging defense opportunities.